Low testosterone plus high fructose triggers fatty liver far worse than either alone

Roughly 40% of adult men worldwide have metabolic dysfunction-associated steatotic liver disease (MASLD), the condition formerly known as non-alcoholic fatty liver disease. Two of its major risk factors, low testosterone and high fructose intake, are both increasingly common. Testosterone levels in men have been declining for decades. Fructose consumption, driven by sweetened beverages and processed foods, has climbed. But how these two factors interact in the liver has been poorly understood.

A study from Osaka Metropolitan University now shows that the interaction is not simply additive. In mouse models, low testosterone and high fructose intake together produce fatty liver that is dramatically worse than either factor alone. The mechanism runs through an unexpected intermediary: the gut microbiome.

Six groups of mice, one clear pattern

The experiment, led by graduate student Hiroki Takahashi and Associate Professor Naoki Harada from the Graduate School of Agriculture, used a precise design. Eight-week-old male mice were either castrated (to eliminate testosterone production) or sham-operated. They were then divided into six groups: sham with normal diet, sham with fructose, sham with fructose plus antibiotics, castration with normal diet, castration with fructose, and castration with fructose plus antibiotics.

Each factor alone caused modest changes in liver triglyceride levels. But when castration and fructose intake were combined, fat accumulation in the liver increased synergistically, far exceeding what either factor produced independently. Liver weight increased in castrated mice receiving fructose but decreased in those also treated with antibiotics, implicating gut bacteria in the mechanism.

Pyruvate as the missing link

The castration-plus-fructose group showed altered gut microbiota composition and changes in liver gene expression. Most notably, levels of cecal pyruvate, a metabolic intermediate produced by gut bacteria, were elevated.

To test whether pyruvate was driving the effect, the researchers performed experiments using mouse-derived primary hepatocytes (liver cells). They found that pyruvate acts synergistically with fructose to promote neutral lipid accumulation in liver cells. In other words, the gut bacteria in testosterone-depleted animals produce excess pyruvate, which then cooperates with dietary fructose to pack fat into liver cells at an accelerated rate.

The antibiotic treatment, which disrupted the gut microbiome, reduced liver weight in the castrated-fructose group. This provides additional evidence that the gut bacteria, rather than testosterone loss or fructose alone, mediate the synergistic effect.

A pathway with clinical implications

The findings connect two trends that are independently well-documented. Declining testosterone is associated with aging, obesity, type 2 diabetes, and sedentary lifestyle. High fructose intake is a product of modern diets, particularly in populations consuming large quantities of sweetened beverages. The mouse study suggests that men who have both risk factors simultaneously face a liver disease burden that neither factor alone would predict.

If the gut microbiota-pyruvate pathway operates similarly in humans, it could open therapeutic approaches. Modifying the gut microbiome through diet, probiotics, or targeted antibiotics might reduce the synergistic damage, even without directly addressing testosterone levels or fructose consumption.

Limitations of a mouse model

The study used castrated mice to model testosterone depletion, which is a more extreme intervention than the gradual testosterone decline seen in aging men. Whether the same synergistic mechanism operates at the moderate reductions in testosterone typical of middle-aged and older men is unknown.

Mouse metabolism differs from human metabolism in several relevant ways. Mice process fructose somewhat differently than humans, and the gut microbiome composition of laboratory mice does not closely match that of humans. The pyruvate pathway identified here would need to be confirmed in human studies or at minimum in human-derived liver cell models exposed to clinically relevant conditions.

The study also does not quantify the fructose intake in terms of human dietary equivalents. Whether the doses used in mice correspond to moderate soda consumption or extreme intake matters for interpreting the clinical relevance.

Harada and Takahashi plan to clarify the mechanism by which pyruvate promotes triglyceride accumulation, with the goal of developing therapeutic drugs and dietary prevention strategies.